April 25, 2015
VIENNA — Patients with genotype 4 and 5 hepatitis C virus benefitted from treatment with Harvoni, according to findings presented at the 2015 International Liver Congress.
Armand Abergel, MD, of Médecine digestive, Chu Estaing at Université d'Auvergne, Clermont Ferrand in France, and colleagues treated more than 80 patients with 12 weeks of Harvoni (ledipasvir/sofosbuvir, Gilead Sciences) at five sites in France. “The cohort was a combination of treatment-naive and treatment-experienced patients,” he said. Half of the cohort had compensated cirrhosis.